Table 1. Characteristics of participants in four annual cross-sectional community nasopharyngeal carriage surveys, 2012–2015, Fiji (n = 8,109 a).
| Characteristics | Summary statistic | |
|---|---|---|
| PCV10 vaccinatedb, n (%) | 1105 (13.6) | |
| Survey year, n (%) | ||
| Pre-PCV10 (2012) | 2025 (25.0) | |
| 1 year post-PCV10 (2013) | 2042 (25.2) | |
| 2 years post-PCV10 (2014) | 2022 (24.9) | |
| 3 years post PCV10 (2015) | 2020 (24.9) | |
| Ethnicity, n (%) | ||
| Fijian of Indian Descent | 3236 (39.9) | |
| iTaukei | 4835 (59.6) | |
| Other | 38 (0.5) | |
| Participant group, n (%) | ||
| Infants (5–8 weeks) | 2006 (24.7) | |
| Toddlers (12–23 months) | 2004 (24.7) | |
| Children (2–6 years) | 2052 (25.3) | |
| Caregivers | 2047 (25.3) | |
| Residential location, n (%) | ||
| Rural | 3944 (48.6) | |
| Urban | 4165 (51.4) | |
| Female sex, n (%) | 4683 (57.8) | |
| Two or more children under five years in the household, n (%) | n = 8106 | |
| 4004 (49.4) | ||
| Low family incomec, n (%) | n = 7831 | |
| 4599 (58.7) | ||
| Symptoms of URTI, n (%) | 2092 (25.8) | |
| Exposure to household cigarette smoke, n (%) | 4353 (53.7) | |
| Antibiotic use in past fortnight, n (%) | n = 8105 | |
| 357 (4.4) | ||
| Pneumococcal carriage, n / N (%) | ||
| Overalld | n = 8061 | |
| 2456 (30.5) | ||
| PCV10 serotypese | n = 8000 | |
| 713 (8.9) | ||
| Non-PCV10 serotypesf | n = 8000 | |
| 1915 (23.9) | ||
| Non-encapsulated pneumococcig | n = 8000 | |
| 390 (4.9) | ||
| Pneumococcal densityh, n, median log10 GE/ml (IQR) | ||
| Overall | 2455, 5.0 (4.2–5.7) | |
| PCV10 serotypes | 713, 4.9 (4.1–5.6) | |
| Non-PCV10 serotypes | 1915, 4.9 (4.1–5.7) | |
| Non-encapsulated pneumococci | 390, 4.3 (3.7–4.9) | |
Abbreviations: PCV10, ten-valent pneumococcal conjugate vaccine; URTI, upper respiratory tract infection; IQR, interquartile range.
a Unless otherwise specified
b Two doses of PCV10 given before the age of 12 months, or one or more doses of PCV10 given at or after 12 months of age[35]
c Weekly family income below the basic needs poverty line (<FJ$175 per week)[28]
d Any pneumococci, including non-encapsulated lineages
e Pneumococcal serotypes included in PCV10 (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F)
f Pneumococcal serotypes not included in PCV10, including non-encapsulated lineages
g Includes carriage of any of the following non-encapsulated lineages: NT, NT1, NT2, NT2/NT3b, NT3a, NT3b, NT4a, NT4b
h Only includes participants who were carriers of indicated pneumococcal types